Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Summit Therapeutics (SMMT) The Motley Fool·2024-10-24 09:13This drugmaker's lead candidate could become a top-selling cancer therapy.To say this has been a big year for Summit Therapeutics (SMMT -2.72%) would be a huge understatement. The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab.The stock market has been pushing up Summit's stock price because there's a chance that ivonescimab could unseat Merck's Keytruda as the world's top-selling cancer treatment. Keytruda racked up a s ...